Manuscripts
Showing 1554 manuscripts.
Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children
Citation
Adriana Weinberg, Lin-Ye Song, Robert Walker, Maria Allende, Terence Fenton, Patricia Patterson, Sharon Appelbaum Nachman, George Kemble, Tingting Yi, Patricia Alexandra Defechereux, Diane W. Wara, Jennifer S. Read, Myron Levin. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. Journal of Acquired Immune Deficiency Syndromes. 2010. 55: 189-96. PMID: 20581690Year
2010
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1057
Substance Use and its Association with Psychiatric Symptoms in Perinatally HIV-infected and HIV-Affected Adolescents.
Citation
Substance Use and its Association with Psychiatric Symptoms in Perinatally HIV-infected and HIV-Affected Adolescents.. AIDS and Behavior. 2010. 14: 1072-82. PMID: 20725774Year
2010
Journal
AIDS and Behavior
Study
P1055
Relationships between the use of second-generation antipsychotics and changes in total cholesterol levels in children and adolescents perinatally infected with HIV
Citation
Relationships between the use of second-generation antipsychotics and changes in total cholesterol levels in children and adolescents perinatally infected with HIV. Neurobehavioral HIV Medicine. 2010. 2010: 39-48. PMID: 20865061Year
2010
Journal
Neurobehavioral HIV Medicine
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
Citation
Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S, IMPAACT P1065 Protocol Team. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.. Pediatric Infectious Disease Journal. 2010. 29: 391-6. PMID: 20431379Year
2010
Journal
Pediatric Infectious Disease Journal
Study
P1065
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study
Citation
David B. Clifford, David W. Haas, David W. Haas, Heather Ribaudo, Heather Ribaudo, Huan Liu, Matthias Schwab, Elke Schaeffeler, Michel Eichelbaum, Alison A. Motsinger, Marylyn D. Ritchie, Ulrich M. Zanger, Edward P. Acosta, Gene D. Morse, Roy (Trip) Gulick, Gregory K. Robbins. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study. Journal of Infectious Diseases. 2010. 202: 717-22. PMID: 20662624Year
2010
Journal
Journal of Infectious Diseases
Pharmacokinetic/Pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)
Citation
Keith Crawford, C. Li, A. Keung, Zhaohui Su, Michael Hughes, Wayne Greaves, Daniel R. Kuritzkes, Roy (Trip) Gulick, Charles Flexner. Pharmacokinetic/Pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). Journal of Acquired Immune Deficiency Syndromes. 2010. 53: 598-605.Year
2010
Journal
Journal of Acquired Immune Deficiency Syndromes
Immune response to Hepatitis B vaccine in HIV-positive subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG Study 5220
Citation
Edgar (Turner) Overton, Minhee Kang, Marion G. Peters, Triin Umbleja, Beverly L. Alston-Smith, Barbara Bastow, Debra DeMarco, Margaret James Koziel, Lori Mong-Kryspin, Heather L. Sprenger, Ji Young Yu, Judith A. Aberg. Immune response to Hepatitis B vaccine in HIV-positive subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG Study 5220. Vaccine. 2010. 28: 5597-604. PMID: 20600512Year
2010
Journal
Vaccine
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection
Citation
Eric S Rosenberg, Barney S. Graham, Ellen Chan, Ronald J. Bosch, Vicki Stocker, Janine Maenza, Martin Markowitz, Susan J. Little, Gary Nabel, Terry L. Flynn, Daniel R. Kuritzkes, Dan H. Barouch. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. Public Library of Science One. 2010. 5: e10555. PMID: 20479938Year
2010
Journal
Public Library of Science One
Antifungal activity of miconazole against recent Candida strains
Citation
Nancy Isham, Mahmoud A. Ghannoum. Antifungal activity of miconazole against recent Candida strains. Mycoses. 2010. 53: 434-7. PMID: 19531099Year
2010
Journal
Mycoses
Quality assessment for therapeutic drug monitoring in AIDS clinical trials group (ACTG 5146): a multicenter clinical trial
Citation
Robin DiFrancesco, Robin DiFrancesco, Susan L Rosenkranz, Lisa Mukherjee, Lisa M. Demeter, Hongyu Jiang, Robert DiCenzo, Carrie Dykes, Prakash Sista, Alex R. Rinehart, Mary Albrecht, Gene D. Morse. Quality assessment for therapeutic drug monitoring in AIDS clinical trials group (ACTG 5146): a multicenter clinical trial. Therapeutic Drug Monitoring. 2010. 32: 458-66. PMID: 20592644Year
2010
Journal
Therapeutic Drug Monitoring